New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 7, 2012
06:10 EDTBRK.A, XOM, LNVGY, MU, CVX, AAPL, RDS.A, BPOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: Wireless carriers are beginning to change the terms of smartphone deals that have mostly benefited phone makers like Apple (AAPL), in a move that could leave consumers paying more for devices like the iPhone, the Wall Street Journal reports...Lenovo Group (LNVGY) said it plans to spend about $800M on a new base to house the development, production and sale of mobile products as it attempts to expand beyond its core PC business, the Wall Street Journal reports...BLOOMBERG: Oil dropped about 3.2% to the lowest level in more than four months after European elections increased speculation that austerity efforts will be derailed and weak jobs data underscored concern the U.S. economy may falter, Bloomberg reports...Individual investors are putting more money into bank-loan funds, adding risk in a search for higher yields and a hedge against inflation as the Fed says it will keep interest rates at near record lows, Bloomberg reports...REUTERS: Micron Technology (MU) won the right to negotiate exclusively to buy Elpida Memory after offering over $2.5B for the failed Japanese chipmaker, sources say, Reuters reports...Warren Buffett said he recently considered an unidentified $22B acquisition for his Berkshire Hathaway (BRK.A), adding that if Berkshire didn't make a major deal this year, it could look at one over $30B next year, Reuters reports.
News For A From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 6, 2015
07:23 EDTAAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 5, 2015
05:29 EDTADako announces FDA approval of new companion diagnostic assay
Subscribe for More Information
October 2, 2015
15:57 EDTALabCorp to offer PD-L1 companion diagnostic
Subscribe for More Information
15:43 EDTAQuest Diagnostics introduces Dako's PD-L1 companion diagnostic for KEYTRUDA
Subscribe for More Information
15:25 EDTAAgilent's Dako confirms FDA approval of NSCLC diagnostic
Dako, an Agilent Technologies (A) company and a worldwide provider of cancer diagnostics, announced the FDA approval of a new companion diagnostic assay that can reveal whether a patient with advanced non-small cell lung cancer, or NSCLC, is likely to respond to a new form of treatment. The approval of PD-L1 IHC 22C3 pharmDx strengthens Dako's portfolio of companion diagnostics and the company's leadership position in developing and commercializing companion diagnostic products. Dako developed PD-L1 IHC 22C3 pharmDx in partnership with Merck (MRK), maker of the anti-PD-1 therapy Keytruda. The FDA approved PD-L1 IHC 22C3 pharmDx for use in the United States. Dako hopes to gain regulatory approval for the new diagnostic in Canada, Europe and other jurisdictions next year.
September 24, 2015
17:04 EDTAMerck, Pfizer to collaborate with Agilent's Dako on Avelumab diagnostic
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use